Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.58 |
| ▸ | ACE2 | Q9BYF1 | 9/20 | 0.58 |
| ▸ | MME | P08473 | 5/20 | 0.57 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | GZMB | P10144 | 1/20 | 0.41 |
| ▸ | AADAT | Q8N5Z0 | 5/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3726276 | 1.00 | ACE (0.58) | ACEACE2MMESTAT3GZMB | |
| SCHEMBL197902 | 1.00 | ACE (0.58) | ACEACE2MMESTAT3GZMB | |
| SCHEMBL12893385 | 1.00 | ACE (0.58) | ACEACE2MMESTAT3GZMB | |
| SCHEMBL10331861 | 0.92 | ACE (0.49) | ACEACE2MME | |
| SCHEMBL7278473 | 0.92 | ACE (0.49) | ACEACE2MME | |
| SCHEMBL7278480 | 0.92 | ACE (0.49) | ACEACE2MME | |
| SCHEMBL16804559 | 0.87 | ACE (0.47) | ACEACE2MMESTAT3GZMB | |
| SCHEMBL7497338 | 0.85 | ACE (0.49) | ACEACE2MMESTAT3GZMB | |
| SCHEMBL27015282 | 0.84 | ACE (0.61) | ACEACE2MMESTAT3GZMB | |
| SCHEMBL14169787 | 0.82 | ACE (0.45) | ACEACE2MMESTAT3GZMB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1647279-A2 | Inhibition of apoptosis using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors | Idun Pharmaceuticals, Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-0929311-B1 | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | IDUN PHARMACEUTICALS INC (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20040058850-A1 | Using caspase inhibitor; antiinflammatory agents | IDUN PHARMACEUTICALS, INC. | 2004-03-25 | — | — | US | disclosed |
| US-6693096-B2 | SUPPRESSING PROTEASE ACTIVITY | IDUN PHARMACEUTICALS, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030186842-A1 | Contacting a cell population with an inhibiting effective amount of a reagent that suppresses the protease activity of at least one member of the interleukin-1beta- converting enzyme (ICE)/CED-3 family | IDUN PHARMACEUTICALS, INC. (US) | 2003-10-02 | — | — | US | disclosed |
| US-6610683-B2 | Programmed cell death; expansion of hematopoietic cells, for prolonging viability of an organ for transplantation, and maintaining viability of cell lines used in bioproduction | IDUN PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6531467-B2 | Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors | IDUN PHARMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| US-6528506-B2 | Viability of organs transplants | IDUN PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20030039661-A1 | Methods, compositions and kits for preserving antigenicity | IDUN PHARMACEUTICALS, INC. | 2003-02-27 | — | — | US | disclosed |
| US-20020147171-A1 | Inhibition of apoptosis using interleukin-1beta converting enzyme (ICE)/CED-3 family inhibitors | IDUN PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | US | disclosed |
| US-6444663-B2 | TREATMENT OF PATIENTS SUFFERING INFLAMMATORY, AUTOIMMUNE AND NEURODEGENERATIVE DISEASES, AND FOR THE PREVENTION OF ISCHEMIC INJURY. | IDUN PHARMACEUTICALS, INC. | 2002-09-03 | — | — | US | disclosed |
| EP-0874850-B1 | NOVEL TRICYCLIC COMPOUNDS FOR THE INHIBITION OF THE ICE/CED-3 PROTEASE FAMILY OF ENZYMES | IDUN PHARMACEUTICALS INC (US) | 2002-04-10 | — | — | EP | disclosed |
| US-20020016321-A1 | Novel tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes | KARANEWSKY DONALD S (US) | 2002-02-07 | — | — | US | disclosed |
| US-20010044415-A1 | Inhibition of apoptosis using interleukin-1B-converting enzyme (ICE)/CED-3 family inhibitors | FRITZ LAWRENCE C (US) | 2001-11-22 | — | — | US | disclosed |
| US-6200969-B1 | CONTACTING CELLS WITH REAGENT WHICH SUPPRESSES PROTEASE ACTIVITY OF INTERLEUKIN-1.BETA.-CONVERTING ENZYME (ICE)/CED-3 FAMILY, INHIBITING APOPTOSIS IN CELL POPULATION TO EXPANDING OR INCREASING SURVIVAL OF CELL POPULATION | IDUN PHARMACEUTICALS, INC. | 2001-03-13 | — | — | US | disclosed |
| US-6187771-B1 | Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes | IDUN PHARMACEUTICALS, INC. | 2001-02-13 | — | — | US | disclosed |
| US-5968927-A | AZEPINO-INDOLE COMPOUNDS; TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND NEURODEGENERATIVE DISEASES, PREVENTION OF ISCHEMIC INJURY | IDUN PHARMACEUTICALS, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0595610-B1 | Benzo-fused lactams | SQUIBB & SONS INC (US) | 1997-05-07 | — | — | EP | disclosed |
| US-5504080-A | Benzo-fused lactams | BRISTOL-MYERS SQUIBB CO. (US) | 1996-04-02 | — | — | US | disclosed |
| EP-0595610-A1 | Benzo-fused lactams | E.R. SQUIBB & SONS, INC. (US) | 1994-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186842-A1 | Contacting a cell population with an inhibiting effective amount of a reagent that suppresses the protease activity of at least one member of the interleukin-1beta- converting enzyme (ICE)/CED-3 family | CASP1, SERPINB1, IL1B | ACE 70/4885ACE2 69/4885MME 91/4885 |
| US-20030039661-A1 | Methods, compositions and kits for preserving antigenicity | CASP1, CASP3, APAF1 | ACE 152/4885ACE2 392/4885MME 176/4885 |
| US-20020147171-A1 | Inhibition of apoptosis using interleukin-1beta converting enzyme (ICE)/CED-3 family inhibitors | CASP1, CASP3, APAF1 | ACE 74/4885ACE2 130/4885MME 205/4885 |
| US-20040058850-A1 | Using caspase inhibitor; antiinflammatory agents | CASP1, PYCARD, CASP3 | ACE 109/4885ACE2 164/4885MME 150/4885 |
| US-20010044415-A1 | Inhibition of apoptosis using interleukin-1B-converting enzyme (ICE)/CED-3 family inhibitors | CASP1, IL1B, APAF1 | ACE 117/4885ACE2 114/4885MME 305/4885 |
| US-20020016321-A1 | Novel tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes | CASP3, CASP1, IDE | ACE 432/4885ACE2 679/4885MME 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.